Significantly lower risk is seen for viral clearance. 2 studies from 2 independent teams (both from the same country) show significant benefit.
Meta analysis using the most serious outcome reported shows 25% [-70‑66%] lower risk, without reaching statistical significance. Results are better for Randomized Controlled Trials and higher quality studies. Early treatment shows efficacy while late treatment does not, consistent with expectations for an antiviral treatment.
Currently there is limited data, with only 31 control events for the most serious outcome in trials to date.
Efficacy is variant dependent. mAb use may create new variants that spread globally1,2, and may be associated with prolonged viral loads, clinical deterioration, and immune escape2-5.
No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Other treatments are more effective. All data and sources to reproduce this analysis are in the appendix.
Covid Analysis et al., Mar 2025, preprint, 1 author.
